What’s the current market cap for Ardent Health Partners stock?

Ardent Health Partners (ARDT) has a market cap of $1.3B as of May 30, 2026.

What is the P/E ratio for Ardent Health Partners stock?

The price to earnings (P/E) ratio for Ardent Health Partners (ARDT) stock is 9.71 as of May 30, 2026.

Does Ardent Health Partners stock pay dividends?

No, Ardent Health Partners (ARDT) stock does not pay dividends to its shareholders as of May 30, 2026.

When is the next Ardent Health Partners dividend payment date?

Ardent Health Partners (ARDT) stock does not pay dividends to its shareholders.

What is the beta indicator for Ardent Health Partners?

Ardent Health Partners (ARDT) does not currently have a Beta indicator.

Buy Ardent Health Partners stock | $ARDT Share Price

13:30

15:10

16:45

18:25

20:00

About Ardent Health Partners

Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S and operating in eight growing mid-sized urban markets across six states Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas. The main focus on people and investments in services and technologies.

Ticker

$ARDT

Sector

Health

Primary listing

NYSE

Employees

22,350

Headquarters

Brentwood, United States

Website

www.ardenthealth.com

ARDT Metrics

BasicAdvanced

$1.3bn

9.71

$0.95

Bulls say / Bears say

Operating cash flow rose by 87% year-over-year to $223 million in Q4 2025, while full-year operating cash flow climbed 49% to $471 million, strengthening Ardent’s liquidity and ability to generate cash.

The IMPACT cost-savings initiative is now projected to save $55 million in 2026, above the previous $40 million target, supporting the company’s anticipated margin growth.

Net leverage improved to 2.5x at the end of FY2025, down from 2.9x a year prior, providing greater financial flexibility for new investments and acquisitions.

The midpoint of fiscal 2026 revenue guidance is $6.55 billion, below analyst consensus of $6.636 billion, which contributed to an 11.8% drop in the share price after the Q4 results.

First-quarter EPS came in at $0.28, missing analysts’ expectations and causing a 6.11% after-hours stock decline, raising concerns about the company's profitability momentum.

Actual patient admissions decreased by 1.1% year-over-year in Q1 2026, indicating operational challenges stemming from severe weather and a milder respiratory season.

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARDT

Capital at risk

Market closed

Upcoming events

No upcoming events